Presidential Cancer Panel's Drug Value, Affordability Recommendations Align With Industry Views
Panel recommends National Academies of Sciences evaluate value frameworks like ICER, identify limitations and strengths and, if necessary, develop a new approach.
You may also be interested in...
The use of patent “march-in” rights as a tool to control the price of drugs developed with US federal funding support remains substantially less popular with the government-funded research community than with politicians.
Sanofi/Regeneron reveal plans to lower price of PCSK9 blocker Praluent to match ICER's updated recommendation, following assessment based on new outcomes data. Decision sparks debate across industry and raises questions about setting precedent on pricing for the future.
President Trump's 2019 federal budget proposal includes plan to exclude manufacturer discounts in the Medicare Part D coverage gap from beneficiaries' out-of-pocket totals, which may be at odds with recently enacted legislation.